Australia markets close in 1 hour
  • ALL ORDS

    7,715.60
    +8.40 (+0.11%)
     
  • ASX 200

    7,409.50
    +4.10 (+0.06%)
     
  • AUD/USD

    0.7172
    +0.0004 (+0.05%)
     
  • OIL

    72.93
    +0.57 (+0.79%)
     
  • GOLD

    1,785.20
    -0.30 (-0.02%)
     
  • BTC-AUD

    69,315.68
    -1,273.99 (-1.80%)
     
  • CMC Crypto 200

    1,302.56
    -2.56 (-0.20%)
     
  • AUD/EUR

    0.6326
    +0.0009 (+0.13%)
     
  • AUD/NZD

    1.0530
    +0.0001 (+0.01%)
     
  • NZX 50

    12,745.93
    -122.39 (-0.95%)
     
  • NASDAQ

    16,394.34
    +68.67 (+0.42%)
     
  • FTSE

    7,337.05
    -2.85 (-0.04%)
     
  • Dow Jones

    35,754.75
    +35.32 (+0.10%)
     
  • DAX

    15,687.09
    -126.81 (-0.80%)
     
  • Hang Seng

    24,217.36
    +220.49 (+0.92%)
     
  • NIKKEI 225

    28,837.10
    -23.52 (-0.08%)
     

UPDATE 1-U.S. FDA declines to approve United-Mannkind's lung disease therapy

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Adds background, Mannkind shares)

Oct 18 (Reuters) - The U.S. Food and Drug Administration has declined to approve a lung disease therapy developed by United Therapeutics and Mannkind Corp, citing an inspection issue at a third-party facility.

United said on Monday the health regulator's draft label for the drug, Tyvaso DPI, includes its use as a treatment for pulmonary arterial hypertension (PAH), as well as PAH associated with interstitial lung disease (PH-ILD).

In its complete response letter, the agency did not cite any deficiencies related to operations at MannKind's device manufacturing and testing facility for Tyvaso DPI.

Shares of Mannkind were down 17.9% at $4.18 in premarket trading.

While PAH is a type of high blood pressure that affects blood vessels in the lungs, PH-ILDs are a group of diseases that cause inflammation and scarring of the lung tissue, making it harder to breathe. (Reporting by Manas Mishra and Bhanvi Satija in Bengaluru; Editing by Ramakrishnan M.)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting